Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective An-Gioplasty; a Randomized Clinical Trial Publisher Pubmed



Helli B¹ ; Gerami H^{2, 3} ; Kavianpour M⁴ ; Heybar H⁵ ; Hosseini SK⁷ ; Haghighian HK^{8, 9}
Source: Endocrine# Metabolic and Immune Disorders - Drug Targets Published:2021

Abstract

Background: Curcumin has demonstrated many pharmacological effects including an-tioxidants, anti-inflammation, eliminating free radicals, anti-tumor, lipid regulation, and anti-coagu-lation. Objective: This study aimed to assess and compare the effects of curcumin and nano-curcumin on lipid profile, oxidative stress, and inflammatory factors related to patient’s heart. Methods: This randomized, double-blind, placebo-controlled clinical trial was conducted on 90 patients undergoing coronary elective angioplasty who were randomly divided into 3 groups. The dos-es administered for 8 weeks were a 500 mg capsule of curcumin daily for the first group and an 80 mg capsule of nano-curcumin for the second group. However, the placebo group received capsules like curcumin. Lipid profile, oxidative stress factors, and inflammatory markers were measured at the baseline and end of the experiment. Results: Statistically significant changes were observed in the total cholesterol (TC), triacylg-lycerol (TG) and low-density lipoprotein cholesterol (LDL-C) in the intervention groups to the control group (p<0.05). Curcumin and nano-curcumin supplementation also exhibited significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA), Super-oxide dismutase (SOD), glutathione peroxidase (GSH-Px), high-sensitivity C-reactive protein (h-s-CRP), Interleukin 1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in comparison to the placebo (p<0.05). Furthermore, the nano-curcumin group compared to the curcumin group demonstrated significant changes (p<0.05) in TC, TG, SOD, MDA and TNF-α levels. Conclusion: The effects of curcumin on nano formula may be better for cardiac patients due to its high bioavailability. Clinical Trial Registrations: The study was registered in the Iranian Registry of Clinical Trials website by the IRCTID: IRCT20141025019669N6. © 2021 Bentham Science Publishers.